[To learn English] Novo Nordisk said on Monday it would lower the U.S. price of its injectable Wegovy obesity drug and pledged to go "all in" on its upcoming oral weight-loss pill, as the firm races to claw back lost ground in the lucrative market. The Danish drugmaker is waiting for a U.S. regulatory decision on the oral version of Wegovy by year-end, with the pill format expected to appeal to patients who prefer to avoid injections of the current Wegovy formulation. 诺和诺德周一表示，将降低其注射用减肥药Wegovy在美国的售价，并承诺全力投入即将上市的口服减肥药，力图在这个利润丰厚的市场中夺回失去的份额。 这家丹麦制药商正在等待美国监管机构在年底前对口服版Wegovy的审批结果。预计这种片剂形式将吸引那些不愿接受注射治疗的患者。 LearnEnglishLeave a remark
